Key result
In patients with paediatric onset multiple sclerosis treated with disease-modifying therapies, female sex and disease duration of 2 or more years prior to treatment predicted a higher relapse rate.
Why the study?
Disease-modifying therapies are increasingly used in children with MS, but most randomized controlled trials evaluating efficacy, safety, and dosing have included only adults.
What are the predictors of treatment outcomes in patients with paediatric onset multiple sclerosis treated with disease-modifying therapies?
Cohort (n=137)
What are the predictors of treatment outcomes in patients with paediatric onset multiple sclerosis treated with disease-modifying therapies?
Earlier initiation of disease-modifying therapies in paediatric onset multiple sclerosis is associated with better prognostic outcomes.
May support earlier DMT initiation in paediatric MS; leaves open randomized confirmation of timing benefits.
BACKGROUND: Disease-modifying therapies (DMT) are increasingly used for children with multiple sclerosis (MS) even though most double-blinded randomized controlled trials evaluating efficacy, safety and dosing strategy of a specific drug have included adults. OBJECTIVE: To investigate predictors of treatment outcomes in patients with paediatric onset MS treated with DMTs. METHODS: = 137) and followed until their 25th birthday. Selected baseline predictors were tested in univariate and multivariate regression models. RESULTS: Multivariate analyses showed that being female and having disease duration for 2 or more years prior to DMT initiation predicted a higher relapse rate. In addition, disease duration and baseline expanded disability status scale (EDSS) predicted both confirmed disability worsening and improvement. We found no difference in treatment outcome between children with MS onset before and after the age of 13 years. CONCLUSIONS: The efficacy of DMT in paediatric onset MS patients is comparable to that seen in adult onset MS patients. Earlier treatment start is associated with a beneficial prognosis in the paediatric cohort.
No takes yet. Share an insight, caveat, or question.
Kopp et al. (2019) conducted a cohort in paediatric onset multiple sclerosis (n=137). Disease-modifying therapies (DMT) was evaluated on Relapse rate and confirmed disability worsening or improvement. In patients with paediatric onset multiple sclerosis treated with disease-modifying therapies, female sex and disease duration of 2 or more years prior to treatment predicted a higher relapse rate.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: